Ceftobiprole for the treatment of pneumonia: a European perspective

Adamantia Liapikou1
Catia Cillóniz2
Antonio Torres2

16th Respiratory Department, Sotiria Chest Diseases Hospital, Athens, Greece; 2Pulmonary Department, Clinic Institute of Thorax (ICT), Hospital Clinic of Barcelona, Spain

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Abstract: Ceftobiprole, a new broad spectrum, parenteral cephalosporin, exhibits potent in vitro activity against a number of Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, and Gram-negative pathogens associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). Ceftobiprole has demonstrated noninferiority in two large-scale pivotal studies comparing it to ceftazidime in HAP, with clinical cure rates 86.6% versus 87.4%, or ceftriaxone in CAP, with clinical cure rates 77% versus 76%, respectively. However, ceftobiprole was inferior in the subgroup of patients undergoing mechanical ventilation. Ceftobiprole has so far demonstrated a good safety profile in preliminary studies, with similar tolerability to comparators. The most commonly observed adverse events of ceftobiprole included headache and gastrointestinal upset. It is the first cephalosporin monotherapy approved in the EU for the treatment of both CAP and HAP (excluding ventilator-associated pneumonia).

Keywords: antibiotic resistance, methicillin-resistant staphylococci, community-acquired pneumonia, hospital-acquired pneumonia, cephalosporins

Introduction
Community-acquired pneumonia (CAP) is a significant cause of morbidity and mortality in developed countries, accounting for a considerable number of hospital admissions, especially in the elderly.1,2 Hospital-acquired pneumonia (HAP) is associated with significant mortality and has been reported to account for >25% of all infections in intensive care units.3 HAPs dramatically increase both the hospital length of stay and the cost of care, and are associated with an overall mortality of 27%–51%,4 the poorer prognosis being reported in the elderly.

The most common bacteria causing CAP are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis,1,2 and the most common bacteria causing HAP are Enterobacteriaceae (such as Klebsiella spp., Enterobacter spp., Serratia spp.), Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii.4,5 S. aureus is the predominant Gram-positive pathogen in HAP and ventilator-associated pneumonia (VAP).

Pathogens that are resistant to antibacterials, particularly methicillin-resistant S. aureus (MRSA) and multidrug-resistant (MDR) S. pneumoniae, are associated with poor outcomes and higher treatment cost.6 Presently, half of the deaths from clinical infection in Europe are associated with MDR bacteria.7,8 Despite a decrease in the incidence of MRSA infections in recent years, the proportion of S. aureus isolates reported as MRSA in 2012 was ≥25% in seven of 30 European countries that provided surveillance reports.9 Koulenti et al10 reported that MRSA was isolated in 16% of patients with nosocomial pneumonia (21.4% in HAP and 14.6% in VAP). A large,
prospective study reporting 474 patients with VAP in Spain found that patients with MRSA VAP had significantly higher in-hospital mortality than patients with VAP caused by other microorganisms (59.5% versus 46.8%; \( P=0.02 \)).

The adequacy of empirical antimicrobial therapy is strongly predictive of hospital survival,\(^1\)\(^-\)\(^5\) making the definition of patients at risk for MDR pathogens a pivotal challenge.

Now with ceftaroline-fosamil and ceftobiprole, a new subclass of antimicrobials, cephalosporins with anti-MRSA activity has been introduced. Ceftobiprole medocaril is a newly approved drug in Europe for the treatment of CAP and HAP (excluding patients with VAP) in adults. This review focuses on the pharmacological properties of ceftobiprole and its clinical efficacy and tolerability in adult patients with CAP and HAP.

**Mechanism of action and antimicrobial activity**

Ceftobiprole medocaril is the prodrug form of ceftobiprole, which is an extended-spectrum cephalosporin that encompasses activity against both Gram-positive and most Gram-negative bacteria, including MRSA. It has bactericidal effects against community-acquired MRSA, vancomycin-resistant *S. aureus*, methicillin-resistant coagulase-negative staphylococci (CoNS), penicillin-resistant *S. pneumoniae*, *Enterococcus faecalis*, *Clostridium perfringens*, *P. aeruginosa*, and 85% of *Enterobacteriaceae*.\(^12\)\(^-\)\(^13\) (Figure 1)

Like other cephalosporins, the binding of ceftobiprole to penicillin-binding proteins (PBPs) interferes with cell wall synthesis, inhibiting cell growth and ultimately leading to bacterial cell death.

Ceftobiprole was refractory to hydrolysis by the common staphylococcal PC1 \( \beta \)-lactamase, the class A TEM-1 \( \beta \)-lactamase, but labile to hydrolysis by class B, class D, and class A extended-spectrum \( \beta \)-lactamases, thus similar to ceftazidime and ceftazidime patterns of action.\(^14\) Ceftobiprole is relatively stable toward AmpC \( \beta \)-lactamases and has a strong affinity for PBPs, including PBP 2A, which mediates resistance to \( \beta \)-lactams in MRSA and methicillin (oxacillin)-resistant CoNS.\(^15\)

It has high affinity against *S. pneumoniae* PBP 2\(x\) in penicillin-resistant and ceftazidime-resistant strains and retains good in vitro activity against them.\(^16\)\(^-\)\(^17\) In a study by Kosowska et al\(^18\) testing its in vitro activity, Ceftobiprole minimum inhibitory concentrations (MICs) were similar to those of carbapenems against nearly all pneumococcal strains tested. Ceftobiprole was especially active against 299 drug-susceptible and -resistant pneumococci, with MIC of 50% (MIC\(_{50}\)) and 90% (MIC\(_{90}\)) values of 0.016 and 0.016 \( \mu \)g/mL (penicillin-susceptible isolates), 0.06 and 0.5 \( \mu \)g/mL (penicillin-intermediate isolates), and 0.5 and 1.0 \( \mu \)g/mL (penicillin-resistant isolates), respectively. Interestingly, during 50 serial passages in the presence of subinhibitory concentrations of antibiotics, the highest MIC achieved for ceftobiprole by a panel of ten pneumococcal isolates was 1 \( \mu \)g/mL.\(^18\)

From the ceftobiprole SENTRY Antibiotic Surveillance Program in Europe (2005–2010), ceftobiprole continues to demonstrate high potency against the causative agents of CAP, with 99.3% of 4,443 *S. pneumoniae* isolates testing susceptible, as well as 2,052 strains of *H. influenzae* inhibited at MIC values of <0.5 \( \mu \)g/mL and 200 strains of *M. catarrhalis* inhibited at MIC values of <0.5 \( \mu \)g/mL.\(^15\) A 2008 US surveillance study on *S. pneumoniae* called, TRUST 12, showed that ceftobiprole was the most potent cephalosporin tested against *S. pneumoniae* with MIC\(_{50}\) (0.015 \( \mu \)g/mL) and MIC\(_{90}\) (0.5 \( \mu \)g/mL), with values two-fold lower than ceftazidime.\(^16\)

However, it is the bactericidal activity against MRSA that sets ceftobiprole apart from other cephalosporins.\(^12\)

In time-kill analysis, ceftobiprole was bactericidal against community-acquired and hospital-acquired MRSA strains.\(^19\)\(^-\)\(^20\) In the SENTRY study, 4,147 of 15,426 (26.9%) *S. aureus* clinical isolates collected from Europe, Turkey, and Israel during 2005–2010 were MRSA, and 98.3% of these strains were susceptible to ceftobiprole.\(^15\) Moreover, ceftobiprole demonstrates in vitro activity against *S. aureus* resistant to linezolid, vancomycin, and daptomycin and ceftaxone-resistant *S. pneumoniae*.\(^16\)\(^-\)\(^17\)\(^-\)\(^21\) The CLASS study, evaluating the in vitro activity of ceftobiprole, published by Rossolini et al\(^22\) across 19 countries, further demonstrates the activity of ceftobiprole against all linezolid nonsusceptible staphylococcal isolates; a significant finding in light of recent reports of linezolid-resistant MRSA and CoNS strains.

Ceftobiprole also displayed bactericidal activity against Gram-negative pathogens comparable to ceftazidime, ceftazidime, or piperacillin-tazobactam in early studies.\(^23\)\(^-\)\(^24\) The SENTRY surveillance study,\(^15\) published in 2014, showed activity against *P. aeruginosa* (64.6% susceptible) by the European Committee on Antimicrobial Susceptibility Testing nonspecies-specific susceptibility breakpoint of 4 \( \mu \)g/mL) that was lower than but similar to those of ceftazidime (78.6% susceptible) and ceftazidime (75.4% susceptible).
It has only moderate activity against *Acinetobacter* spp. and is not active against *Proteus vulgaris*, ceftazidime-nonsusceptible *P. aeruginosa*, *Bacteroides* spp., and some extended-spectrum β-lactamase-producing isolates.

Ceftobiprole has limited activity against Gram-negative anaerobes such as *Bacteroides fragilis* and *non-fragilis Bacteroides* spp. but is generally active against *Clostridium* spp. and *Fusobacterium* spp. (MIC$_{90}$ 8 mg/L).$^{25,26}$

**Pharmacokinetic/pharmacodynamic (PK/PD) profile**

Like other β-lactams, ceftobiprole exhibits concentration-independent killing; studies in animals and of in vitro PK models have shown that the duration that the unbound concentration of an antibiotic remains above the MIC as a percentage of the dosing interval (%fT > MIC) is the PK/PD index that best correlates with drug-related response.

Müller et al.$^{27}$ using data from a randomized double-blind Phase III clinical trial, explored the relationship of ceftobiprole exposure with microbiological and clinical outcomes in patients with nosocomial pneumonia. According to regression analyses, a significant ($P=0.0029$) correlation was seen between %fT > MIC and clinical cure when %fT > MIC was $>51.1%$; a significant ($P>0.0001$) correlation was also observed for microbiological eradication when %fT > MIC was $>62.2%$.

Single- and multiple-dose PKs of ceftobiprole have been evaluated in healthy volunteers.$^{28}$ With ceftobiprole 500 mg every 8 hours infused over 2 hours, the probability of attaining a 50% fT > MIC target was 80% for an MIC of 4 mg/L in subjects with normal renal function and 98.8% and 99.9% for MRSA and methicillin-sensitive *S. aureus*, respectively, with MIC$_{90}$ 1 and 0.5 mg/L, respectively.$^{29}$

Utilizing Monte Carlo simulations, the probability of target attainment corresponding to 60% fT/MIC for ceftobiprole 500 mg every 8 hours (2-hour infusion) is 87.8% for AmpC-producing bacilli, with an MIC$_{90}$ of 16 μg/mL and 94.1% for non-AmpC-producing bacilli for an MIC$_{90}$ of $<0.25$ μg/mL.$^{30,31}$

Peak levels of the active drug in plasma were achieved at the end of the 30-minute infusion. The apparent volume of distribution was similar to those reported to other β-lactams (18–20/L). Ceftobiprole demonstrates a low percentage of protein binding (16%)$^{13}$ and is independent of the drug concentration across the range of 0.5–100 μg/mL. Renal clearance and urinary excretion of the free drug decreased while the elimination half-life increased with decreasing renal function. Patients with a creatinine clearance of 30<50 mL/min should have the dosing interval adjusted to every 12 hours. In patients with a creatinine clearance $<30$ mL/min, the dosing regimen should be 250 mg every 12 hours as a 2-hour intravenous infusion.$^{13,19,29,30}$

Ceftobiprole exhibits a modest postantibiotic effect (30 minutes) for MRSA and a more prolonged postantibiotic effect (2 hours) for penicillin-resistant pneumococci.$^{31}$ It does not inhibit the cytochrome P-450 isoenzyme system, so the possibility of drug–drug interactions is low.

**Clinical efficacy in pneumonia**

Because of its broad-spectrum activity against lower respiratory tract pathogens, ceftobiprole was evaluated in the treatment of CAP and HAP.

**Clinical trials in CAP**

Firstly, in a study conducted to compare the in vivo activity of ceftobiprole with that of ceftriaxone in a mouse model of acute pneumococcal pneumonia there was no significant difference in cumulative survival rates between the two antibiotics, but 100% survival was obtained at a five-fold lower total daily ceftobiprole dose than the dose of ceftriaxone used.$^{32}$

The clinical efficacy of ceftobiprole in CAP demonstrated by the results of a randomized, double-blind, comparative study of ceftobiprole medocaril (500 mg every 8 hours infused over 2 hours) versus ceftriaxone (2 g once daily for 30-minute infusions) with or without linezolid (600 mg every 12 hours as 1-hour infusions, 7–14 days) in the treatment of subjects hospitalized with CAP.$^{33}$ By the study design, linezolid was allowed for subjects with proven or suspected MRSA or ceftriaxone-resistant *S. pneumoniae*. Patients were stratified before randomization based on the Pneumonia Patient Outcomes Research Team (PORT); Pneumonia Severity Index (PSI), corresponding to class IV and V severity, and need for addition of linezolid versus placebo. If after day 3, patients met stability criteria, they were eligible to switch to oral cefuroxime 500 mg every 12 hours.

A typical bacterial pathogen was isolated at baseline in 28.8% of the intention-to-treat (ITT) population, with *S. pneumoniae* (n=68) and *H. influenzae* (n=26) being the most common. The ceftobiprole group had more polymicrobial infection than did the comparator group (20% versus 8%, $P=0.016$).

The severity of pneumonia at baseline had no effect on clinical cure rates at the test of cure visit between the two groups.

For the 469 clinically evaluable (CE) patients, cure rates were 86.6% versus 87.4% for ceftobiprole and comparator, respectively; in the ITT analysis of 638 CAP patients, these
cure rates were 76.4% versus 79.3%, respectively, demonstrating the noninferiority of ceftobiprole compared to ceftriaxone in CAP therapy.

For the secondary end-point of clinical cure in patients with a pneumonia severity index ≥91, the cure rates for the above regimens were 90.2% and 84.5% compared with 85.6% and 88.3% for those with lower scores, respectively. In patients with CAP complicated by bacteremia, cure rates were 85.7% versus 85.7%; and with presence of systemic inflammatory response syndrome 84.6% versus 86.7% for ceftobiprole and ceftriafone linezolid therapy, respectively.

Referring to the secondary efficacy endpoint of microbiological eradication, noninferiority between the ceftobiprole and comparator groups was observed also. Subgroup analyses showed that among those who switched to oral cefuroxime, microbiological eradication rates were significantly lower with ceftobiprole medocaril than with ceftriaxone ± linezolid (89% versus 100%; n=37 and n=41, respectively).

**Clinical trials in HAP**

A Phase III randomized double-blind study was designed to compare the ceftobiprole medocaril (500 mg every 8 hours, infused over 2 hours) versus linezolid (600 mg every 12 hours as a 1-hour intravenous infusion) plus ceftazidime (2 g every 8 hours as a 2-hour intravenous infusion) for 7–14 days in 781 recruited subjects with clinical diagnosis of HAP, including VAP.34

The overall cure rates in the ITT population were 50% for ceftobiprole and 52.8% for combination therapy, and in the CE population, 69.3% in the ceftobiprole group and 71.6% demonstrating the noninferiority of ceftobiprole compared to the comparator group.34

Among patients without VAP, the cure rate in the ITT population was 77.4% in the ceftobiprole group and 76.3% in the comparator group, and in the CE population, it was 38.5% and 56.7%, respectively.

In the CE analysis set, a higher proportion of HAP (excluding VAP) patients in the ceftobiprole group than in the ceftazidine/linezolid group (CE, 86.9% versus 78.4%, respectively) showed early improvement (4 days after onset of therapy) (Table 1). The largest difference was for patients with a baseline culture positive for MRSA, with 94.7% in the ceftobiprole group having early improvement versus 52.6% in the ceftazidine/linezolid group (difference, 42.1%).35

The overall microbiological eradication rate in the ceftobiprole group was 62.9% (73/116) compared to 67.5% (81/120) in the ceftazidime/linezolid group. However, subjects with clinical cure 73/86 (85%) in the ceftobiprole group and 81/94 (86%) in the other group, had an outcome of microbiological eradication.

Of note, in patients with non-VAP, clinical cure rates were similar between ceftobiprole medocaril and ceftazidime plus linezolid recipients who had *P. aeruginosa* at baseline. Only for *A. baumannii* and *Haemophilus* spp. were numerically lower clinical cure and microbiological eradication rates observed in the ceftobiprole group.

Thirty-day pneumonia-specific mortality was similar between the two treatment groups, 5.9% and 5.6%, respectively (difference, 0.3%).

However, ceftobiprole was inferior in the subgroup of patients with VAP.34 The clinical cure rate in the CE
population with VAP favored the linezolid/ceftazidime arm over the ceftobiprole arm, 56.7% versus 38.5%, respectively \((P<0.05)\). Interestingly, in mechanically ventilated patients with non-VAP, clinical outcomes were in favor of ceftobiprole medocaril, suggesting that mechanical ventilation by itself is not associated with poor outcomes. In fact, of the 16 VAP patients \(\leq 45\) years with head trauma that were randomized to ceftobiprole, 12 were characterized as treatment failures compared to two out of the four assigned to the linezolid/ceftazidime group.

There are different explanations for this result: 1) It is thought by the authors that the small sample size and the substantial heterogeneity in baseline characteristics in the VAP subgroup may have contributed to the differential outcomes,\(^34\) and 2) the inferior outcome may have been the consequence of suboptimal concentrations of ceftobiprole at the site of infection, as a result of a change in the volume distribution owing to capillary leak from mechanical ventilation.\(^36\)

In a more recent review,\(^37\) it was reported that in patients with normal PK and non-VAP, ceftobiprole is effective for the treatment of HAP in the recommended doses, but it is unlikely to achieve the desired PD targets when PK parameters are altered in VAP (eg, increased volume of distribution and clearance). Consequently, ceftobiprole medocaril is not approved for patients with VAP.

### Tolerability

Ceftobiprole medocaril is generally well tolerated in patients with HAP or CAP in Phase III trials.\(^33,34\) The incidence of serious adverse events (AEs) in ceftobiprole medocaril versus comparator groups were 36.3% versus 31.9% in the HAP trial and 11.3% versus 11.5% in the CAP trial, respectively.\(^36\)

The most common treatment-related AEs occurring in ceftobiprole recipients in the trials in patients with HAP or CAP included nausea, dysgeusia, diarrhea, infusion site reactions, vomiting, hepatic enzyme elevations, and hyponatremia (Table 2).

Particularly in the Nicholson et al trial,\(^33\) in patients with CAP the overall incidence of treatment-related AEs was higher in the ceftobiprole group, primarily owing to differences in rates of self-limited nausea and vomiting. There were no differences between groups for injection-site AEs, hyponatremia, or hepatic AEs.

### Table 1 Efficacy of intravenous ceftobiprole medocaril in adult patients with HAP or CAP

<table>
<thead>
<tr>
<th>Parameter</th>
<th>CAP(^33)</th>
<th>HAP(^34)</th>
<th>VAP(^34)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drugs</strong></td>
<td>BPR(n=314)</td>
<td>CRO + LZN(n=324)</td>
<td>BPR(n=391)</td>
</tr>
<tr>
<td><strong>Clinical cure</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT, % (n)</td>
<td>76.4 (240)</td>
<td>79.3 (257)</td>
<td>49.9 (195)</td>
</tr>
<tr>
<td>CE, % (n)</td>
<td>86.6 (200)</td>
<td>87.4 (208)</td>
<td>69.3 (174)</td>
</tr>
<tr>
<td><strong>Microbiological eradication</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITT, % (n)</td>
<td>80.5 (70)</td>
<td>81.4 (79)</td>
<td>39 (105)</td>
</tr>
<tr>
<td>ME, % (n)</td>
<td>88.2 (60)</td>
<td>90.8 (69)</td>
<td>53.7 (87)</td>
</tr>
</tbody>
</table>

**Abbreviations:** BPR, ceftobiprole; CAP, community-acquired pneumonia; CAZ, ceftazidime; CE, clinically evaluable; CRO, ceftriaxone; HAP, hospital-acquired pneumonia; iTT, intent-to-treat; LZN, linezolid; ME, microbiologically evaluable; VAP, ventilator-associated pneumonia.

### Table 2 Safety profile of ceftobiprole in clinical trials of CAP and HAP

<table>
<thead>
<tr>
<th>Adverse events</th>
<th><strong>CAP(^33)</strong></th>
<th><strong>HAP(^34)</strong></th>
<th><strong>VAP(^34)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>70%</td>
<td>64.6%</td>
<td>77.5%</td>
</tr>
<tr>
<td>One AE</td>
<td>36%</td>
<td>26%</td>
<td>25%</td>
</tr>
<tr>
<td>Serious AE</td>
<td>11.3%</td>
<td>11.5%</td>
<td>36.3%</td>
</tr>
<tr>
<td>Nausea</td>
<td>7%</td>
<td>2%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>5%</td>
<td>2%</td>
<td>1.6%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>0</td>
<td>3.1%</td>
</tr>
<tr>
<td>Anemia</td>
<td>0</td>
<td>0</td>
<td>5%</td>
</tr>
<tr>
<td>Hepatic enzyme elevations</td>
<td>7%</td>
<td>7%</td>
<td>0.8%</td>
</tr>
<tr>
<td>Infusion site reactions</td>
<td>7%</td>
<td>5%</td>
<td>2.1%</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>1%</td>
<td>3%</td>
<td>4.4%</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>0</td>
<td>0</td>
<td>1.3%</td>
</tr>
</tbody>
</table>

**Abbreviations:** AE, adverse events; CAP, community-acquired pneumonia; CAZ, ceftazidime; CRO, ceftriaxone; HAP, hospital-acquired pneumonia; LZN, linezolid.
In the Awad et al HAP study, ceftobiprole patients had fewer treatment-related events of diarrhea than patients treated with ceftazidime/linezolid (3.1% and 6.5%, respectively), whereas hyponatremia was observed more frequently with ceftobiprole than with ceftazidime/linezolid (4.4% and 2.6%, respectively).

One study found that the most common patient complaint was “caramel-like taste disturbances” (dysgeusia) when the medication was administered at higher doses. This was found to be most likely a result of the metabolism of ceftobiprole medocaril to diacetyl.

The drug is contraindicated in patients with severe hypersensitivity (eg, anaphylactic reaction) to any other type of β-lactam antibacterial agent.

**Regulatory affairs**

Following approval under the European decentralized procedure, ceftobiprole has received national licenses in Austria, Belgium, Denmark, Finland, France, Germany, Norway, Spain, Sweden, and the United Kingdom; national authorization in Italy and Luxembourg; and reimbursement and pricing authorization in several countries including Spain is ongoing. It is also in preregistration stage in Switzerland for these indications.

Basilea Pharmaceutica Ltd. entered into an agreement with Quintiles in July 2014 for commercialization in key European countries of Zevtera®/Mabelio® (ceftobiprole medocaril) for patients with HAP and CAP.

In November 2008, the US Food and Drug Administration (FDA) declined to approve ceftobiprole, citing data integrity concerns with two of the supporting studies. The FDA determined that data from the two mentioned studies (BAP00154 and BAP00414) could not be relied on; inspections and audits of approximately one third of the clinical trial sites found the data from a large proportion of these sites to be unreliable or unverifiable.

**Expert opinion**

One of the main challenges in the management of HAP and CAP is to overcome the resistance issues, which have become so important and common over the past several years. Management of pulmonary infections caused by resistant Gram-positive pathogens, particularly MRSA, remains a significant challenge. An analysis of pneumococcal resistance rates in the US spanning the years 1998 to 2009 demonstrated remarkable increases in nonsusceptibility to commonly used β-lactam agents.

Treatment guidelines for HAP recommend rapid empiric therapy with combinations of antibiotics based on local resistance patterns and patient risk factors. It has been recommended that initial empirical monotherapy should be used whenever possible to reduce the risk of MDR development and adverse outcomes.

Cephalosporins are effective first-line therapies for many bacterial infections. Ceftobiprole, a new parenteral cephalosporin has notable activity against Gram-positive pathogens, including MRSA, and some major Gram-negative pathogens, particularly *P. aeruginosa*. It was shown to be noninferior to ceftazidime plus linezolid for the treatment of HAP and ceftriaxone ± linezolid for the treatment of CAP (in hospitalized patients) in two randomized clinical trials.

Regarding, clinical efficacy in CAP treatment, further studies are needed to determine the efficacy of ceftobiprole in more severely ill CAP patients.

Alternatively, the inferiority of ceftobiprole to linezolid plus ceftazidime in the treatment of VAP raises serious concern about the efficacy of the drug in achieving adequate concentrations in the alveolar compartment of ventilated patients. We believe that if a larger dose of ceftobiprole had been used, the results might have been different. After all, a dose of 1,000 mg every 8 hours has been well tolerated in healthy volunteers.

Therefore, further investigation assessing the efficacy of ceftobiprole medocaril in patients with VAP may be warranted.

Although ceftobiprole was not shown to induce resistance in clinical trials, recent studies demonstrate that low- and high-level ceftobiprole resistance develop when isolates are exposed to sub-MIC concentrations. As with other cephalosporins, ceftobiprole may lose activity as the degree of expression of efflux pumps increases by bacteria such as *Pseudomonas* spp. Although it is impossible to know how quickly resistance to ceftobiprole will emerge in a clinical setting, the emergence of ceftobiprole resistance via chromosomal mutation was not readily observable in the laboratory.

Ceftobiprole medocaril is generally well tolerated in clinical trials, and 10% of patients discontinued the treatment because of AEs. Importantly, it has no significant impact on the normal human intestinal flora, and *Clostridium difficile* colitis is uncommon with ceftobiprole medocaril.

Ceftobiprole offers a number of advantages in potency, spectrum, and β-lactamase stability compared to currently marketed third-generation carbapenems and other β-lactams. It may be a powerful antibiotic prescribed as monotherapy in serious CAP and HAP (excluding VAP) as initial empirical treatment.

**Conclusion**

Ceftobiprole is a new parenteral cephalosporin with bactericidal activity against Gram-positive pathogens including...
MRSA, responsible for pneumonia, while preserving the anti-Gram-negative activity of existing broad-spectrum cephalosporins. Clinical data from two large Phase III studies have demonstrated that ceftobiprole medocaril is noninferior to the combination of high-dose ceftazidime and linezolid for the treatment of HAP (excluding VAP) and noninferior to high-dose ceftriaxone with or without linezolid for the treatment of CAP requiring hospitalization. Therefore ceftobiprole represents a safe and effective treatment of hospitalized CAP and HAP (excluding VAP).

Acknowledgment
Catia Cillóniz and Antonio Torres are supported by: SGR 2014/661, Ciber de Enfermedades Respiratorias (Ciberes CB06/06/0028), Pneumonia Corporate Research Program (CRP). The Ciberes is an initiative of the ISCIII. SGR: Support to research groups of Catalunya.

Disclosure
The authors report no conflicts of interest in this work.

References


